IDEXX LABORATORIES INC /DE — Director's Dealing 2022

Nov 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2022-11-07

Reporting Person: MAZELSKY JONATHAN JAY (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-07	Common Stock	M	24002	$52	Acquired	75536.6426	Direct
2022-11-07	Common Stock	S	900	$378.5951	Disposed	74636.6426	Direct
2022-11-07	Common Stock	S	2000	$379.4994	Disposed	72636.6426	Direct
2022-11-07	Common Stock	S	500	$380.8520	Disposed	72136.6426	Direct
2022-11-07	Common Stock	S	3704	$382.8057	Disposed	68432.6426	Direct
2022-11-07	Common Stock	S	2716	$383.2864	Disposed	65716.6426	Direct
2022-11-07	Common Stock	S	3018	$384.4651	Disposed	62698.6426	Direct
2022-11-07	Common Stock	S	392	$385.0122	Disposed	62306.6426	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-07	Non-Qualified Stock Option (right-to-buy)	$52	M	24002	Disposed	2023-12-04	Common Stock (24002)	Direct

Footnotes

F1: Includes 17 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2022

F2: Represents the weighted average price of the shares sold ranging from a low of $377.99 to a high of $378.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $379.10 to a high of $380.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $380.68 to a high of $381.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $381.94 to a high of $382.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Represents the weighted average price of the shares sold ranging from a low of $382.95 to a high of $383.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F7: Represents the weighted average price of the shares sold ranging from a low of $383.97 to a high of $384.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F8: Represents the weighted average price of the shares sold ranging from a low of $384.98 to a high of $385.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F9: Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F10: Not applicable.